Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020
JAMA · 18.07.2023 · 330 (3) · 278
DOI: 10.1001/jama.2023.10753 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 18.07.2023. Verfasst von Michael Anne Kyle und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Medicare Part D, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
This study examines the exposure of Medicare Part D beneficiaries to utilization management, such as prior authorization, for oral oncology drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Förderung
- NCI NIH HHS
Zitieren
APA
Kyle, M. A., Dusetzina, S. B., & Keating, N. L. (2023). Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020. JAMA, 330(3), 278. https://doi.org/10.1001/jama.2023.10753
Vancouver
Kyle MA, Dusetzina SB, Keating NL. Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020. JAMA. 2023;330(3):278. doi:10.1001/jama.2023.10753
BibTeX
@article{Kyle2023,
author = {Kyle, Michael Anne and Dusetzina, Stacie B and Keating, Nancy L},
title = {Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020},
journal = {JAMA},
year = {2023},
volume = {330},
number = {3},
pages = {278},
doi = {10.1001/jama.2023.10753}
}
EUVIMED